SCHEMBL16401498

SCHEMBL16401498

CCOC(=O)C(=[N+]=[N-])c1ccc(C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
EPHX2 P34913 1/20 0.43
PPARG P37231 1/20 0.43
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
PTPN1 P18031 1/20 0.41
GSK3B P49841 1/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
MAOB P27338 1/20 0.41
GPR35 Q9HC97 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707474 0.85 GPR35 (0.47) NPSR1CES2POLBGAAALDH1A1
SCHEMBL14638979 0.83 CES2 (0.47) CES2CES1MAPTPTPN1GSK3B
SCHEMBL28399426 0.83 MAPT (0.50) NPSR1CES2CES1EPHX2PPARG
SCHEMBL25380495 0.83 POLB (0.49) EPHX2PPARGPOLBSMN1; SMN2NPC1
SCHEMBL28321122 0.83 SMN1; SMN2 (0.45) CES2CES1POLBSMN1; SMN2NPC1
SCHEMBL29001221 0.81 CA1 (0.56) NPSR1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL12398654 0.81 CES2 (0.44) CES2CES1PPARGMAPTALDH1A1
SCHEMBL17338792 0.80 KMT2A (0.50) NPSR1CES2CES1NPC1RAB9A
SCHEMBL31258015 0.80 KMT2A (0.44) NPSR1POLBSMN1; SMN2GAAMAPT
SCHEMBL28783011 0.80 SMN1; SMN2 (0.49) NPSR1CES2CES1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116082237-A Nitrogen-containing heterocyclic compound and preparation method thereof 安徽中医药大学 2023-05-09 CN disclosed
CN-111116368-B Green preparation method of aryl alpha-keto acid ester compound 河南师范大学 2022-07-22 CN disclosed
CN-111116368-A Green preparation method of aryl α -keto acid ester compound 河南师范大学 2020-05-08 CN disclosed
US-20160115508-A1 PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-04-28 US disclosed
EP-3003317-A2 PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS University Of Rochester (US) 2016-04-13 EP disclosed
WO-2014197591-A2 PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS UNIVERSITY OF ROCHESTER (US) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115508-A1 PARTHENOLIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTICANCER AGENTS CYP3A43, POR, CYP3A4 NPSR1 4392/4885CES2 98/4885CES1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.